Opendata, web and dolomites

HOPE SIGNED

Host Protective Engineering of Cancer Immunity by Targeting the Intracellular Immune Checkpoint NR2F6

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HOPE project word cloud

Explore the words cloud of the HOPE project. It provides you a very rough idea of what is the project "HOPE" about.

either    inseparable    recurrence    resistance    crossroads    molecular    clinic    therapeutic    prerequisite    complexity    distal    genetic    reducing    tumours    cells    initiation    validate    combinatorial    therapy    cancer    microenvironment    epidemiologically    cas9    spread    delineate    organs    reveal    human    immunity    functional    checkpoint    poorly    metastases    predisposition    shown    clinical    inhibitors    pronged    supports    signalling    pkc    generation    events    axis    mission    strategies    perturbation    team    immune    host    experimentally    transcriptomic    startegies    biochemical    overcome    anti    clinically    pd    screening    intrinsic    preventive    technologies    crispr    network    biological    nsclc    latter    rendering    profoundly    nr2f6    genomic    prevalent    proteomic    employing    entities    oncology    elucidated    prevents    risk    protective    first    lymphocyte    potentially    influence    site    chronic    tumour    limitations    signatures    lung    adverse    successful    tools    mechanisms    combination    effector    rejecting    functions    node    cell    immunological    progression    inflammation    prevention   

Project "HOPE" data sheet

The following table provides information about the project.

Coordinator
MEDIZINISCHE UNIVERSITAT INNSBRUCK 

Organization address
address: CHRISTOPH PROBST PLATZ 1
city: INNSBRUCK
postcode: 6020
website: www.i-med.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 2˙484˙325 €
 EC max contribution 2˙484˙325 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2023-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE UNIVERSITAT INNSBRUCK AT (INNSBRUCK) coordinator 2˙484˙325.00

Map

 Project objective

'Because of its biological complexity, cancer is still poorly understood. Chronic inflammation has been shown, both experimentally and epidemiologically, to be a predisposition to, and also an inseparable aspect of clinically prevalent cancer entities. Therefore, a detailed understanding of both tumour and immune cell functions in cancer progression is a prerequisite for more successful therapeutic startegies. My team was the first to reveal the lymphocyte-intrinsic PKC/NR2F6 axis as an essential signalling node at the crossroads between inflammation and cancer. It is the mission of this project to identify molecular signatures that influence the risk of developing tumours employing established research tools and state-of-the-art genetic, biochemical, proteomic and transcriptomic as well as large scale CRISPR/Cas9 perturbation screening-based functional genomic technologies. Defining this as yet poorly elucidated effector pathway with its profoundly relevant role would enable development of preventive and immune-therapeutic strategies against NSCLC lung cancer and potentially also against other entities. Our three-pronged approach to achieve this goal is to: (i) delineate biological and clinical properties of the immunological PKC/NR2F6 network, (ii) validate NR2F6 as an immune-oncology combination target needed to overcome limitations to 'first generation anti-PD-1 checkpoint inhibitors' rendering T cells capable of rejecting tumours and their metastases at distal organs and (iii) exploit human combinatorial T cell therapy concepts for prevention of immune-related adverse events as well as of tumour recurrence by reducing opportunities for the tumour to develop resistance in the clinic. Insight into the functions of NR2F6 pathway and involved mechanisms is a prerequisite for understanding how the microenvironment at the tumour site either supports tumour growth and spread or prevents tumour initiation and progression, the latter by host-protective cancer immunity.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HOPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HOPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More  

ORGANITRA (2019)

Transport of phosphorylated compounds across lipid bilayers by supramolecular receptors

Read More  

BALANCE (2019)

Mapping Dispersion Spectroscopically in Large Gas-Phase Molecular Ions

Read More